share_log

bluebird bio | DEFA14A: Others

bluebird bio | DEFA14A: Others

bluebird bio | DEFA14A：其他
美股SEC公告 ·  11/01 16:10

Moomoo AI 已提取核心信息

bluebird bio, Inc., a biotechnology company, has issued a definitive additional materials proxy statement to its stockholders, urging them to vote in favor of Proposal 4 at the upcoming Annual Meeting on November 6, 2024. The proposal concerns a reverse stock split aimed at restoring stockholder value and ensuring the company's continued listing on Nasdaq. The company is currently at risk of being delisted due to its stock price and requires additional capital to reach its expected breakeven point in the second half of the following year. The reverse stock split would also allow bluebird bio to raise additional capital by increasing the number of authorized shares. Independent proxy advisory firms ISS and Glass Lewis have recommended in favor of Proposal 4. The company's President & CEO, Andrew Obenshain, has reached out to stockholders for support, providing easy voting instructions and offering assistance through a proxy solicitor.
bluebird bio, Inc., a biotechnology company, has issued a definitive additional materials proxy statement to its stockholders, urging them to vote in favor of Proposal 4 at the upcoming Annual Meeting on November 6, 2024. The proposal concerns a reverse stock split aimed at restoring stockholder value and ensuring the company's continued listing on Nasdaq. The company is currently at risk of being delisted due to its stock price and requires additional capital to reach its expected breakeven point in the second half of the following year. The reverse stock split would also allow bluebird bio to raise additional capital by increasing the number of authorized shares. Independent proxy advisory firms ISS and Glass Lewis have recommended in favor of Proposal 4. The company's President & CEO, Andrew Obenshain, has reached out to stockholders for support, providing easy voting instructions and offering assistance through a proxy solicitor.
生物技术公司bluebird bio, Inc.已向股东发布了一份明确的额外材料代理声明，敦促他们在2024年11月6日即将举行的年度股东大会上投票支持第4号提案。该提案涉及一项旨在恢复股东价值并确保公司继续在纳斯达克上市的股票拆分。由于股票价格低迷且需要额外资金以达到预期的亏损平衡点，该公司目前面临被退市的风险。股票拆分还将使bluebird bio通过增加授权股份数量筹集额外资金。独立的代理机构ISS和Glass Lewis建议支持第4号提案。该公司的总裁兼首席执行官安德鲁·奥本沙恩已与股东联系，提供简便的投票说明，并通过代理律师提供帮助。
生物技术公司bluebird bio, Inc.已向股东发布了一份明确的额外材料代理声明，敦促他们在2024年11月6日即将举行的年度股东大会上投票支持第4号提案。该提案涉及一项旨在恢复股东价值并确保公司继续在纳斯达克上市的股票拆分。由于股票价格低迷且需要额外资金以达到预期的亏损平衡点，该公司目前面临被退市的风险。股票拆分还将使bluebird bio通过增加授权股份数量筹集额外资金。独立的代理机构ISS和Glass Lewis建议支持第4号提案。该公司的总裁兼首席执行官安德鲁·奥本沙恩已与股东联系，提供简便的投票说明，并通过代理律师提供帮助。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间